Clinical trials: Systemic Juvenile Idiopathic Arthritis, active
Arthritis, Juvenile, Arthritis, Juvenile Idiopathic
Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
The proposed study aims to evaluate the effectiveness of hypnotherapy as a non-pharmacological intervention for managing pain and anxiety during needle-related medical procedures in children aged 5 to 17 years.
- Conditions
- Arthritis, Juvenile, Arthritis, Juvenile Idiopathic, Lupus Erythematosus, Systemic, Dermatomyositis, Juvenile
- Trial name
- NCT07349667
- Testing
- Hypnotherapy
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aarhus University Hospital
Still Disease
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease
- Trial name
- NCT07625384
- Testing
- Goflikicept, Olokizumab
- Where
- 25 sites in Russia
- Volunteers
- 52 people
- Sponsor
- R-Pharm International, LLC
Still's Disease, Adult-Onset, Systemic Inflammation
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD).
- Conditions
- Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
- Trial name
- NCT03510442
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis
Clinical Features and Treatment of Systemic JIA in Children
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- CST-SJIA (NCT07814963)
- Testing
- Tocilizumab (Actemra®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07000916
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Université Catholique de Louvain
Active Systemic Juvenile Idiopathic Arthritis
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A multicenter, randomized Phase II/III clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
- Trial name
- NCT05925452
- Testing
- GenaKumab
- Where
- 10 sites in China
- Volunteers
- 290 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Systemic Juvenile Idiopathic Arthritis
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- NCT04088396
- Testing
- Baricitinib, Tocilizumab
- Where
- 55 sites in Argentina, Belgium and 12 more
- Volunteers
- 58 people
- Sponsor
- Eli Lilly and Company
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome
AutoInflammatory Disease Alliance Registry (AIDA)
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system.
- Conditions
- Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
- Trial name
- AIDA (NCT05200715)
- Testing
- No intervention is foreseen by the protocol.
- Where
- 112 sites in Algeria, Australia and 20 more
- Volunteers
- 3,500 people
- Sponsor
- University of Siena
Rheumatic Diseases, Arthritis
Pain-Sleep in Rheumatic Disease
Overall, our understanding of how pain and sleep are experienced and how they can be treated in teenagers with rheumatic diseases is limited.
- Conditions
- Rheumatic Diseases, Arthritis, Lupus, Lupus Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07775612
- Testing
- Better Nights, Better Days for Youth
- Volunteers
- 43 people
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this…
- Trial name
- SKYPS (NCT02991469)
- Testing
- Sarilumab SAR153191 (REGN88)
- Where
- 40 sites in Argentina, Canada and 12 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Systemic Juvenile Idiopathic Arthritis (sJIA)
Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases
Literature data suggest that elevated blood values of IL-18 and IL-18 Binding Protein and alterations in their ratio may be significantly correlated with various autoinflammatory diseases, such as systemic juvenile idiopathic…
- Trial name
- NCT06718049
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Still´s Disease
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
- Trial name
- NCT07203001
- Testing
- MAS825
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Familial Mediterranean Fever, Still Disease
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including…
- Conditions
- Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
- Trial name
- NCT07517250
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Still Disease, Autoinflammatory Disease
Clinical Autoinflammatory Disease Cohort
Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysregulation of the innate immune system, characterized by recurrent fever, systemic inflammation, and involvement of specific organs.
- Trial name
- CAID (NCT07126145)
- Testing
- Not applicable- observational study
- Volunteers
- 1,000 people
- Sponsor
- RenJi Hospital
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Juvenile Idiopathic Arthritis (JIA)
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor…
- Trial name
- The Treat-JIA (NCT07904780)
- Testing
- Adalimumab, Etanercept, Golimumab
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Oslo University Hospital
Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
- Trial name
- NCT07184450
- Testing
- BCMA/CD70-targetd CAR-T
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Rheumatoid Arthritis, Palindromic Arthritis
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Social determinants of health (SDoH), defined by the World Health Organization as "the conditions in which people are born, grow, work, live and age and the wider set of forces and systems shaping the conditions of daily life"…
- Conditions
- Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- RAISE (NCT05715463)
- Testing
- Resource sheets, Community Resource Specialist, Nurse Navigator
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Brigham and Women's Hospital